Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Abstract

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

1 - 40 . (canceled) 
     
     
         41 . A pharmaceutical composition comprising
 (1) a first compound of the formula:   
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         (2) a sulfonylurea; and 
         (3) a pharmaceutically acceptable carrier. 
       
     
     
         42 . The pharmaceutical composition of  claim 41  wherein the sulfonylurea is selected from:
 (1) tolbutamide; and 
 (2) glipizide; 
 or a pharmaceutically acceptable salt thereof; 
 
     
     
         43 . A method of treating Type 2 diabetes comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a first compound of the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; and a sulfonylurea. 
       
     
     
         44 . The method of  claim 43  wherein the sulfonylurea is selected from:
 (1) tolbutamide; and 
 (2) glipizide; 
 or a pharmaceutically acceptable salt thereof.